Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 255

1.

On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.

ElSawy KM, Verma CS, Joseph TL, Lane DP, Twarock R, Caves LS.

Cell Cycle. 2013 Feb 1;12(3):394-404. doi: 10.4161/cc.23511. Epub 2013 Jan 16.

2.

Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies.

Joseph TL, Madhumalar A, Brown CJ, Lane DP, Verma CS.

Cell Cycle. 2010 Mar 15;9(6):1167-81. Epub 2010 Mar 15.

PMID:
20190571
3.

In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.

Bozzi F, Conca E, Laurini E, Posocco P, Lo Sardo A, Jocollè G, Sanfilippo R, Gronchi A, Perrone F, Tamborini E, Pelosi G, Pierotti MA, Maestro R, Pricl S, Pilotti S.

Lab Invest. 2013 Nov;93(11):1232-40. doi: 10.1038/labinvest.2013.107. Epub 2013 Sep 9.

4.

Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.

Xia M, Knezevic D, Tovar C, Huang B, Heimbrook DC, Vassilev LT.

Cell Cycle. 2008 Jun 1;7(11):1604-12. Epub 2008 Mar 17.

PMID:
18520179
5.

MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin.

Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J.

J Biol Chem. 2006 Nov 3;281(44):33030-5. Epub 2006 Aug 11.

6.

On the origin of the stereoselective affinity of Nutlin-3 geometrical isomers for the MDM2 protein.

ElSawy KM, Verma CS, Lane DP, Caves LS.

Cell Cycle. 2013 Dec 15;12(24):3727-35. doi: 10.4161/cc.27273. Epub 2013 Nov 21.

7.
8.

Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors.

Vaseva AV, Yallowitz AR, Marchenko ND, Xu S, Moll UM.

Cell Death Dis. 2011 May 12;2:e156. doi: 10.1038/cddis.2011.39.

9.

Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.

Geng QQ, Dong DF, Chen NZ, Wu YY, Li EX, Wang J, Wang SM.

Int J Oncol. 2013 Dec;43(6):1935-42. doi: 10.3892/ijo.2013.2138. Epub 2013 Oct 14.

PMID:
24126697
10.

Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction.

Shan B, Li DW, Brüschweiler-Li L, Brüschweiler R.

J Biol Chem. 2012 Aug 31;287(36):30376-84. doi: 10.1074/jbc.M112.369793. Epub 2012 Jul 17.

11.

Monitoring Ligand-Induced Protein Ordering in Drug Discovery.

Grace CR, Ban D, Min J, Mayasundari A, Min L, Finch KE, Griffiths L, Bharatham N, Bashford D, Kiplin Guy R, Dyer MA, Kriwacki RW.

J Mol Biol. 2016 Mar 27;428(6):1290-1303. doi: 10.1016/j.jmb.2016.01.016. Epub 2016 Jan 23.

12.

Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.

Pazgier M, Liu M, Zou G, Yuan W, Li C, Li C, Li J, Monbo J, Zella D, Tarasov SG, Lu W.

Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4665-70. doi: 10.1073/pnas.0900947106. Epub 2009 Mar 2.

13.

Stochastic modeling and simulation of the p53-MDM2/MDMX loop.

Cai X, Yuan ZM.

J Comput Biol. 2009 Jul;16(7):917-33. doi: 10.1089/cmb.2008.0231.

14.

Designing dual inhibitors of Mdm2/MdmX: Unexpected coupling of water with gatekeeper Y100/99.

Lee XA, Verma C, Sim AYL.

Proteins. 2017 Aug;85(8):1493-1506. doi: 10.1002/prot.25310. Epub 2017 May 16.

PMID:
28425639
15.

E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.

Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F.

Oncogene. 2008 Sep 11;27(40):5303-14. doi: 10.1038/onc.2008.164. Epub 2008 Jun 2.

PMID:
18521084
16.

Effect of the Flexible Regions of the Oncoprotein Mouse Double Minute X on Inhibitor Binding Affinity.

Qin L, Liu H, Chen R, Zhou J, Cheng X, Chen Y, Huang Y, Su Z.

Biochemistry. 2017 Nov 7;56(44):5943-5954. doi: 10.1021/acs.biochem.7b00903.

PMID:
29023092
17.

Molecular basis for the inhibition of p53 by Mdmx.

Popowicz GM, Czarna A, Rothweiler U, Szwagierczak A, Krajewski M, Weber L, Holak TA.

Cell Cycle. 2007 Oct 1;6(19):2386-92. Epub 2007 Oct 12.

PMID:
17938582
18.

A site-directed mutagenesis study of the MdmX RING domain.

Egorova O, Mis M, Sheng Y.

Biochem Biophys Res Commun. 2014 May 16;447(4):696-701. doi: 10.1016/j.bbrc.2014.04.065. Epub 2014 Apr 19. Erratum in: Biochem Biophys Res Commun. 2015 Aug 7;463(4):1341. Mis, Monika [added].

PMID:
24755078
19.

Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.

Qin L, Yang F, Zhou C, Chen Y, Zhang H, Su Z.

J Am Chem Soc. 2014 Dec 31;136(52):18023-33. doi: 10.1021/ja509223m. Epub 2014 Dec 17. Retraction in: J Am Chem Soc. 2015 Nov 18;137(45):14546.

PMID:
25453499
20.

Computational studies of difference in binding modes of peptide and non-peptide inhibitors to MDM2/MDMX based on molecular dynamics simulations.

Chen J, Zhang D, Zhang Y, Li G.

Int J Mol Sci. 2012;13(2):2176-95. doi: 10.3390/ijms13022176. Epub 2012 Feb 17.

Supplemental Content

Support Center